Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system.
Relapsing-remitting MS (RRMS) is the most common disease course and is characterized
by periods of worsening neurologic symptoms (“relapses”) followed by partial or complete
recovery. Incomplete recovery from relapses may contribute to worsening neurologic function (“disability progression”). Over time, RRMS may transition to secondary progressive MS (SPMS). SPMS is characterized by irreversible disability progression that occurs in the absence of, or independent of, relapses.
2019 Review: Secondary Progressive MS
Intervention of Interest: Siponimod (Novartis)
Below you will find the final documents from the assessment review process: